IP Library Granted Patent US 9,249,243
Granted Patent B2
US 9,249,243 · App. 13/963,919 · Granted Feb 2, 2016

Antibacterial antisense oligonucleotide and method

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,249,243
App. No.
13/963,919
Granted
Feb 2, 2016
Kind
B2
Abstract

A method for enhancing, by at least 10 fold, the antibacterial activity of an antisense oligonucleotide composed of morpholino subunits linked by phosphorus-containing intersubunit linkages. The method includes one or both of: conjugating an arginine-rich carrier to a 3′ or 5′ end of the oligonucleotide and modifying the oligonucleotide to contain 20%-50% intersubunit linkages that are positively charged at physiological pH. Also disclosed is an antisense oligonucleotide having enhanced antibacterial activity by virtue of one or both modifications.

Claims (47)

1. A compound having the following formula (I):

or a salt thereof, wherein:

R 1 is H or trityl;

R 2 is H or

and

R 3 is H or a linkage to a solid support.

2. The compound of claim 1 , wherein the compound has the following structure:

3. The compound of claim 1 , wherein R 2 is

4. The compound of claim 3 , wherein the compound has the following structure:

5. The compound of claim 3 , wherein the compound has the following structure:

wherein R 3 is a linkage to a solid support.

6. The compound of claim 3 , wherein the compound has the following structure:

wherein R 3 is a linkage to a solid support.

7. The compound of claim 1 , wherein the solid support comprises aminomethylpolystyrene.

8. An oligomer of 10 to 40 morpholino subunits connected by phosphorous-containing linkages of the formula:

wherein:

each X is at, each occurrence, independently alkyl, alkoxy, thioalkoxy, —NR 2 or 1-piperazinyl, wherein at least one of the X moieties in the oligomer is 1-piperazinyl;

each R is, at each occurrence, independently hydrogen or C 1 -C 6 alkyl; and

each B is, at each occurrence, independently a purine or pyrimidine base-pairing moiety selected from adenine, cytosine, guanine, uracil, thymine and inosine, wherein the 5′ terminal morpholino subunit comprises a group of the formula:

wherein:

each R is defined as above;

R 2 is H or

and

R 3 is H or a linkage to a solid support.

9. The oligomer of claim 8 , wherein each X that is not 1-piperazinyl is —NR 2 , wherein each R is methyl.

10. A solid support covalently bound to a compound having the following structure:

wherein:

R 1 is H or trityl; and

R 3 is a linkage to the solid support.

11. The solid support of claim 10 , wherein R 1 is H.

12. The solid support of claim 10 , wherein R 1 is trityl.

13. The solid support of claim 10 , wherein the solid support comprises aminomethylpolystyrene.

14. The oligomer of claim 8 , wherein the 5′ terminal morpholino subunit is of a formula:

15. The oligomer of claim 8 , wherein the oligomer is of a formula:

wherein:

X and B are as defined in claim 8 ;

Z is an integer from 4 to 19;

R 4 is selected from H, trityl and acetyl; and

R 5 is selected from an electron pair, C 1 -C 6 alkyl and H.

16. The oligomer of claim 15 , wherein each X that is not 1-piperazinyl is —NR 2 , wherein each R is methyl.

17. The oligomer of claim 15 , wherein each B is independently selected from adenine, cytosine, guanine, uracil and thymine.

18. A compound of formula:

or a pharmaceutically acceptable salt thereof, wherein:

Z is an integer from 3 to 19;

each X is, at each occurrence, independently alkyl, alkoxy, thioalkoxy, —NR 2 or 1-piperazinyl, wherein at least one of the X moieties in the oligomer is 1-piperazinyl;

each R is, at each occurrence, independently hydrogen or C 1 -C 6 alkyl; and

each B is independently a purine or pyrimidine base-pairing moiety selected from adenine, cytosine, guanine, uracil, thymine, and inosine.

Assignments (1)
SECURITY INTEREST Recorded May 7, 2025
From: SAREPTA THERAPEUTICS, INC.
To: JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT
Reel/Frame 071218/0445 →